Fundamental leadership · SEC EDGAR · no analyst estimates · as of 2026-09-10
Which industries lead on earnings and sales, today. As of 2026-09-10, 4,465 companies clear the eligibility gates and 1,340 rank Leader or Strong on filed EPS and revenue growth. The strongest industry group is Precious Metals with 29 Leader or Strong names. 19.9% of eligible companies also sit in the top relative-strength quintile — fundamentals and price agreeing.
Theme
| Ticker | Company | Rank | Δ3wk | Verdict | EPS YoY | Sales YoY | Margin Δ | 6M RS | Filed |
|---|---|---|---|---|---|---|---|---|---|
| LQDA | Liquidia Corporation Common StockHuman Therapeutics | 99 | ±0 | Leader | to profit↑ | >+999% | >+10,000 bps | 94 | 2026-08-12 |
| NBIX | Neurocrine Biosciences IncHuman Therapeutics | 97 | ±0 | Leader | +31% | +39% | +384 bps | 75 | 2026-07-31 |
| TGTX | TG Therapeutics, Inc.Human Therapeutics | 97 | ±0 | Leader | -71% | +70% | -186 bps | 96 | 2026-08-05 |
| ARQT | Arcutis Biotherapeutics, Inc. Common StockHuman Therapeutics | 96 | ±0 | Leader | to profit | +59%↓ | +4050 bps | 46 | 2026-08-05 |
| ARGX | argenx SE American Depositary SharesHuman Therapeutics | 95 | ±0 | Leader | +53% | +89% | +2577 bps | 85 | 2026-03-19 |
| LLY | Eli Lilly & Co.Obesity & Weight-Loss TherapeuticsHuman Therapeutics | 93 | ±0 | Leader | +26% | +48% | +1051 bps | 66 | 2026-08-05 |
| ALNY | Alnylam Pharmaceuticals, Inc.Human Therapeutics | 92 | ±0 | Leader | — | +67%↓ | — | 23 | 2026-07-30 |
| IMCR | Immunocore Holdings plc American Depositary SharesHuman Therapeutics | 91 | ±0 | Leader | loss narrowed 90% | +18% | +780 bps | 54 | 2026-08-06 |
| URGN | UroGen Pharma Ltd. Ordinary SharesHuman Therapeutics | 91 | ±0 | Leader33 | loss narrowed 73%↑ | +199%↑ | +9580 bps | 97 | 2026-08-05 |
| INSM | Insmed, Inc.Human Therapeutics | 90 | ±0 | Leader33 | loss narrowed 96%↑ | +296%↑ | >+10,000 bps | 38 | 2026-08-06 |
| CRSP | CRISPR Therapeutics AGHuman Therapeutics | 89 | ±0 | Strong | loss narrowed 61%↑ | >+999%↑ | <-10,000 bps | 56 | 2026-08-03 |
| IOVA | Iovance Biotherapeutics, Inc. Common StockHuman Therapeutics | 89 | ±0 | Strong33 | loss narrowed 67%↑ | +66%↑ | +7730 bps | 94 | 2026-08-06 |
| KRYS | Krystal Biotech, Inc. Common StockHuman Therapeutics | 88 | ±0 | Strong | +39% | +24% | +615 bps | 85 | 2026-08-03 |
| TARS | Tarsus Pharmaceuticals, Inc. Common StockHuman Therapeutics | 88 | ±0 | Strong | loss narrowed 10% | +69%↓ | +2517 bps | 70 | 2026-08-06 |
| INCY | Incyte Genomics IncHuman Therapeutics | 87 | ±0 | Strong | +84% | +21% | +2609 bps | 83 | 2026-07-28 |
| ADMA | ADMA Biologics, Inc.Human Therapeutics | 86 | -1 | Strong | +14% | +2% | +1100 bps | 13 | 2026-08-05 |
| PTCT | PTC Therapeutics, Inc.Human Therapeutics | 86 | -1 | Strong | to profit | +102% | -2825 bps | 53 | 2026-07-30 |
| SNDX | Syndax Pharmaceuticals, Inc.Human Therapeutics | 85 | -1 | Strong | loss narrowed 34% | +92%↓ | >+10,000 bps | 23 | 2026-08-04 |
| ABBV | ABBVIE INC.Human Therapeutics | 80 | -1 | Strong | +290% | +10% | — | 65 | 2026-08-03 |
| BEAM | Beam Therapeutics Inc. Common StockHuman Therapeutics | 80 | ±0 | Strong | loss widened 18%↓ | -94% | >+10,000 bps | 40 | 2026-08-04 |
| KYMR | Kymera Therapeutics, Inc. Common StockHuman Therapeutics | 80 | ±0 | Strong33 | loss narrowed 35%↑ | +466%↑ | >+10,000 bps | 89 | 2026-08-05 |
| RYTM | Rhythm Pharmaceuticals, Inc. Common StockHuman Therapeutics | 74 | ±0 | Strong | loss narrowed 3%↑ | +47% | +2991 bps | 67 | 2026-08-04 |
| EXEL | Exelixis IncHuman Therapeutics | 73 | ±0 | Strong | +26%↓ | +11%↑ | +851 bps | 86 | 2026-08-05 |
| MDGL | Madrigal Pharmaceuticals, Inc. Common StockHuman Therapeutics | 73 | ±0 | Strong | loss widened 5% | +71%↓ | +3497 bps | 78 | 2026-07-30 |
| QURE | uniQure N.V.Human Therapeutics | 71 | ±0 | Strong | loss widened 4% | +127% | <-10,000 bps | 98 | 2026-07-29 |
| AZN | AstraZeneca PLCObesity & Weight-Loss TherapeuticsHuman Therapeutics | 70 | ±0 | Strong | +27% | +12% | — | 28 | 2026-02-24 |
| CYTK | Cytokinetics Inc.Human Therapeutics | 67 | ±0 | Average | loss widened 34%↓ | -57% | <-10,000 bps | 70 | 2026-08-06 |
| GSK | GSK plc American Depositary Shares (Each representing two Ordinary Shares)Human Therapeutics | 66 | ±0 | Average | +123% | +4% | +1147 bps | 33 | 2026-07-28 |
| VRTX | Vertex Pharmaceuticals IncHuman Therapeutics | 65 | ±0 | Average | +8% | +12% | +359 bps | 56 | 2026-08-04 |
| AMGN | Amgen IncObesity & Weight-Loss TherapeuticsHuman Therapeutics | 63 | ±0 | Average | +65% | +10% | +653 bps | 51 | 2026-08-05 |
| RARE | Ultragenyx Pharmaceutical Inc.Human Therapeutics | 63 | ±0 | Average | loss narrowed 23% | +29% | +914 bps | 15 | 2026-08-05 |
| MRNA | Moderna, Inc. Common StockHuman Therapeutics | 61 | ±0 | Average | loss narrowed 8% | +2% | -4268 bps | 98 | 2026-07-31 |
| BMY | Bristol-Myers Squibb Co.Human Therapeutics | 60 | -1 | Average | +153% | +6%↑ | +1039 bps | 59 | 2026-07-30 |
| ARWR | Arrowhead Research CorporationObesity & Weight-Loss TherapeuticsHuman Therapeutics | 58 | -1 | Average | loss widened 8% | +171% | -1498 bps | 88 | 2026-08-04 |
| ACAD | Acadia Pharmaceuticals Inc.Human Therapeutics | 57 | -1 | Average | +13% | +16%↑ | -1566 bps | 80 | 2026-08-05 |
| NVO | Novo-Nordisk A/SObesity & Weight-Loss TherapeuticsHuman Therapeutics | 51 | -1 | Average | +2% | +6% | -289 bps | 67 | 2026-02-04 |
| REGN | Regeneron Pharmaceuticals IncObesity & Weight-Loss TherapeuticsHuman Therapeutics | 51 | ±0 | Average | -5% | +17% | -228 bps | 53 | 2026-07-30 |
| TVTX | Travere Therapeutics, Inc. Common StockHuman Therapeutics | 51 | -1 | Average | loss widened 164%↓ | +48%↓ | +4474 bps | 98 | 2026-08-04 |
| UTHR | United Therapeutics CorpHuman Therapeutics | 45 | ±0 | Average | +13% | -2%↓ | -261 bps | 39 | 2026-08-05 |
| ADCT | ADC Therapeutics SAHuman Therapeutics | 43 | -1 | Average | loss narrowed 78% | +3%↓ | +7904 bps | 4 | 2026-08-13 |
| BMRN | BioMarin Pharmaceuticals IncHuman Therapeutics | 41 | -1 | Average | -81% | +20% | -2095 bps | 62 | 2026-08-06 |
| CORT | Corcept Therapeutics Inc.Human Therapeutics | 40 | ±0 | Average | +24% | +32% | -1347 bps | 99 | 2026-07-29 |
| DNLI | Denali Therapeutics Inc. Common StockHuman Therapeutics | 38 | ±0 | Average | loss narrowed 6% | — | — | 47 | 2026-08-06 |
| ZLAB | Zai Lab Limited American Depositary SharesHuman Therapeutics | 38 | ±0 | Average | loss widened 25% | -3% | -142 bps | 80 | 2026-08-06 |
| IONS | Ionis Pharmaceuticals, Inc. Common StockHuman Therapeutics | 37 | -1 | Average | to loss | -41% | — | 22 | 2026-07-29 |
| MIRM | Mirum Pharmaceuticals, Inc. Common StockHuman Therapeutics | 37 | ±0 | Average | loss widened 783% | +38%↓ | <-10,000 bps | 63 | 2026-08-05 |
| ALKS | Alkermes Inc. plcHuman Therapeutics | 36 | -1 | Average | -100% | +27% | -1783 bps | 93 | 2026-07-28 |
| TAK | Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)Human Therapeutics | 32 | ±0 | Average | -26% | +7% | +246 bps | 49 | 2026-06-17 |
| RXRX | Recursion Pharmaceuticals, Inc. Class A Common StockHuman Therapeutics | 30 | ±0 | Laggard | loss narrowed 39%↓ | -60%↓ | +1409 bps | 38 | 2026-08-05 |
| SRPT | Sarepta Therapeutics,, Inc. Common StockHuman Therapeutics | 30 | ±0 | Laggard | to loss | -36% | — | 71 | 2026-08-05 |
| NTLA | Intellia Therapeutics, IncHuman Therapeutics | 28 | ±0 | Laggard | loss narrowed 18%↓ | -46%↓ | >+10,000 bps | 38 | 2026-08-06 |
| GILD | Gilead Sciences IncHuman Therapeutics | 19 | ±0 | Laggard | to loss | +10% | -3609 bps | 48 | 2026-08-06 |
| BIIB | Biogen Inc. Common StockHuman Therapeutics | 17 | -1 | Laggard | +31% | +2% | -152 bps | 66 | 2026-07-29 |
| PFE | Pfizer Inc.Obesity & Weight-Loss TherapeuticsHuman Therapeutics | 14 | -1 | Laggard | to loss | +3% | -990 bps | 51 | 2026-08-04 |
| CAPR | Capricor Therapeutics IncHuman Therapeutics | 12 | ±0 | Laggard | loss widened 23% | -8% | — | 4 | 2026-08-14 |
| LEGN | Legend Biotech Corporation American Depositary SharesHuman Therapeutics | 12 | -1 | Laggard | to loss | — | — | 42 | 2026-03-10 |
| RVMD | Revolution Medicines, Inc. Common StockHuman Therapeutics | 12 | ±0 | Laggard | loss widened 134%↓ | — | — | 96 | 2026-08-05 |
| PRAX | Praxis Precision Medicines, Inc. Common StockHuman Therapeutics | 10 | ±0 | Laggard | loss narrowed 13%↑ | -100% | — | 68 | 2026-08-06 |
| XENE | Xenon Pharmaceuticals IncHuman Therapeutics | 10 | ±0 | Laggard | loss widened 4%↑ | — | — | 48 | 2026-08-06 |
| ORKA | Oruka Therapeutics, Inc. Common StockHuman Therapeutics | 8 | ±0 | Laggard | loss widened 156%↑ | — | — | 98 | 2026-08-10 |
| VKTX | Viking Therapeutics, IncObesity & Weight-Loss TherapeuticsHuman Therapeutics | 8 | ±0 | Laggard | loss widened 90%↑ | — | — | 36 | 2026-07-29 |
| ZYME | Zymeworks Inc.Human Therapeutics | 1 | ±0 | Laggard | to loss↓ | -91%↑ | <-10,000 bps | 57 | 2026-08-06 |
Every US common stock and ADR in the universe is ranked on fundamental growth from the numbers companies actually filed with the SEC — no analyst estimates, no forward projections. TickerStance reads EDGAR XBRL company facts directly.
To qualify, a company must have at least six quarters of EPS and revenue history available and the most-recent filing must be no older than 200 days. That gate keeps the rankings grounded in current operating conditions rather than stale data.
Two growth factors are computed: recent year-over-year growth (latest quarter vs the same quarter last year) blended with a three-year trend score. Both factors are percentile-ranked universe-wide so a rank of 90 means the company grows faster than 90% of its peers, regardless of absolute size. The two factor percentiles are then combined into a single 1-99 fundamentals rank.
Operating margin is tracked as context — a company whose margins are expanding while growing revenue is a stronger story than one shrinking margins to buy growth — but margin level is not a direct rank input. Industries, sectors, and themes inherit their rank from the median of their members, so a strong cluster is one where most constituent companies score well, not just a few outliers.
The RS overlap metric shows what share of a cluster's eligible companies sit in the top relative-strength quintile (6M RS rank ≥ 80). When a fundamentally strong group also carries broad price leadership, it has both the earnings story and the institutional sponsorship — the combination that historically precedes sustained outperformance.
Every US common stock and ADR with sufficient SEC filing history gets a 1-99 fundamentals rank: EPS and revenue growth factors are computed from filed XBRL data, percentile-ranked across the universe, and blended. Ranks of 90+ are Leaders, 70-89 Strong, 30-69 Average, below 30 Laggards. Industries, sectors, and themes are then ranked by their members' median rank.
SEC EDGAR XBRL company facts — the numbers companies actually filed. No analyst estimates, no forward guidance, no third-party data vendor.
Sign-aware: a narrowed loss counts as improvement, a widened loss as deterioration, a swing to profit as a turnaround. Conventional percent math misreads losses (a loss shrinking from -$0.12 to -$0.07 is improvement, not "down 42%"), so the table says "loss narrowed 42%" instead of printing a misleading percentage.
The change in a group's median fundamentals rank versus 15 and 30 trading days ago — the classic "improving group" read. Positive means the group is gaining rank. Dashes mean the history window isn't available yet.
Once per US trading day after the close. The as-of date in the header is the snapshot date.